iPSC Drug Development Summit on September 09-10, 2026 in Boston, United States

As induced pluripotent stem cell (iPSC) therapies move from promise to proof, the 6th iPSC Drug Development Summit returns at a critical moment for the field. With landmark regulatory progress, late-stage clinical programs advancing, and unprecedented investment flowing into iPSC platforms, the focus has shifted decisively toward scalability, manufacturability, and commercial readiness.

This is the only industry summit dedicated exclusively to advancing iPSC-derived therapies from early research through clinical translation and GMP-ready manufacturing. Bringing together biopharma innovators, academic leaders, regulators, and investors, the meeting provides an end-to-end view of the development challenges teams are navigating today and the solutions being applied in practice.

Across two focused tracks covering preclinical development and process development and CMC, attendees will gain real-world insights into genome editing strategies, donor and cell line selection, functional QC, scale-up, cryopreservation, regulatory alignment, and investment readiness. The agenda features 25+ expert speakers from leading organizations including Astellas Pharma, BlueRock Therapeutics, Aspen Neuroscience, Vertex Pharmaceuticals, and more, sharing new clinical data and hard-won development lessons across indications such as Parkinson's disease, ocular disorders, diabetes, and oncology.

Designed for scientists, engineers, and decision-makers actively building iPSC pipelines, this summit offers unparalleled opportunities to pressure‑test strategies, benchmark against leaders, and connect with the ecosystem shaping the future of iPSC therapeutics.

Free to attend for qualified biopharma professionals and academics working on iPSC therapies.

URLs:

Tickets: https://go.evvnt.com/3619978-2?pid=10008

Brochure: https://go.evvnt.com/3619978-3?pid=10008

Time: 7:30 AM - 4:30 PM

Prices:

Conference - Solution Provider Pricing: USD 3899.00,

Conference - Biopharma and Academics: USD 0.00

Speakers: Yanzheng Liu, Senior Director, Aspen Neuroscience, Rachel Knopp, Lead, iPSC Characterization Team, Astellas Pharma, Steven Kattman, External Diligence and Competitive Intelligence Advisor, Astellas Pharma, Yongting Wang, Head of Biology, Cell and Gene Therapy Research, Astellas Pharma, JC Chi, Director, BeOne Medicines, William Hendriks, Director – PSC Biology, BlueRock Therapeutics, Aaron Goldman, Director ‑ Drug Resistance Group and Faculty, Instructor in Medicine/ Operating Partner, Harvard Medical School/ Broad Oak Capital, Daniel Friedman, Manging Director, BroadOak Capital, Damien Zanker, Head of Clinical Manufacturing, Cartherics Pty, Eric Law, Head of CMC Regulatory Affairs, Century Therapeutics, Alex Ng, Chief Scientific Officer and Co‑Founder, GC Therapeutics, Marcella Garita-Hernandez, Head of iPS Core, Harvard Medical School, Allen Feng, Founder and Chief Scientific Officer, HebeCell, Yong Zhang, Senior Director, Intellia Therapeutics, Seongho Bae, Director of Research and Development, Kadis Bio, Howard Federoff, Chief Medical Officer, Kenai Therapeutics, Anna Falk, Director at Lund University Advanced Therapy Medicinal Products, Lund University, Marianna Weener, Senior Researcher, Massachusetts Eye and Ear, Luyan Jiao, Vice President – New Drug Development, Nuwacell, Noelle Hutchins, Partner, Omega Funds, Ron Cohen, Chief Executive Officer, Oryon Cell Therapies, Mehmet Zeynel, Cilek Assistant Professor of Medical Genetics, SUNY Upstate Medical University, Matt Buckley, Chief Executive Officer and Co‑Founder, Theseus Therapies, George Savvidis, iPSC Research and Development, Thymmune Therapeutics, Cici Wang, Process Development Engineering, Vertex Pharmaceuticals, Mahendra Rao, Chief Scientific Officer, Vita Therapeutics, John Steele, Director, Voyager Therapeutics